サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1123196

心血管薬の世界市場（2022年～2028年）

Global Cardiovascular Drug Market Research and Forecast 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 160 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
心血管薬の世界市場（2022年～2028年）
出版日: 2022年07月25日
発行: Orion Market Research
ページ情報: 英文 160 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心血管薬の市場規模は、予測期間中にCAGRで1.2%の成長が予測されています。ライフスタイルや食習慣の変化は、市場に影響を与え、市場を牽引している要因の1つです。また、環境汚染の拡大や医療費の増加なども、市場の成長に大きく寄与している要因と推定されています。

当レポートでは、世界の心血管薬市場について調査分析し、セグメント分析、地域分析、予測、企業プロファイルなどを提供しています。

目次

第1章 レポートサマリー

第2章 市場の概要と考察

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場の決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の心血管薬市場：薬品タイプ別
    • 抗凝固薬
    • 抗高脂血症薬
    • カルシウム拮抗薬
    • レニン-アンジオテンシン系阻害薬
    • その他
  • 世界の心血管薬市場：疾患タイプ別
    • 不整脈
    • 冠動脈疾患
    • 高脂血症
    • 高血圧症
    • 末梢動脈疾患
  • 世界の心血管薬市場：流通チャネル別
    • 病院薬局
    • オンライン薬局
    • 小売薬局

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第7章 企業プロファイル

  • Abbott
  • AMGEN
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Catalent, Inc
  • DAIICHI SANKYO CO., LTD.
  • Lilly
  • F. HOFFMANN-LA ROCHE LTD.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Probo Medical, LLC
  • Novartis AG
  • Merck & Co., Inc.
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
図表

LIST OF TABLES

  • 1. GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL CARDIOVASCULAR DRUGS MARKET BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL ANTI-CLOTTING AGENTS MARKET BY REGION,2020-2027 ($ MILLION)
  • 4. GLOBAL ANTIHYPERLIPIDEMIC MARKET BY REGION,2020-2027 ($ MILLION)
  • 5. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET BY REGION,2020-2027 ($ MILLION)
  • 6. GLOBAL RENIN-ANGIOTENSIN SYSTEM BLOCKERS MARKET BY REGION,2020-2027 ($ MILLION)
  • 7. GLOBAL OTHER MARKET BY REGION,2020-2027 ($ MILLION)
  • 8. GLOBAL CARDIOVASCULAR DRUGS MARKET BY DISEASE TYPE,2020-2027 ($ MILLION)
  • 9. GLOBAL ARRHYTHMIA MARKET BY REGION,2020-2027 ($ MILLION)
  • 10. GLOBAL CORONARY ARTERY DISEASE MARKET BY REGION,2020-2027 ($ MILLION)
  • 11. GLOBAL HYPERLIPIDEMIA MARKET BY REGION,2020-2027 ($ MILLION)
  • 12. GLOBAL HYPERTENSION MARKET BY REGION,2020-2027 ($ MILLION)
  • 13. GLOBAL PERIPHERAL ARTERY DISEASE MARKET BY REGION,2020-2027 ($ MILLION)
  • 14. GLOBAL CARDIOVASCULAR DRUGS MARKET BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)
  • 15. GLOBAL HOSPITAL PHARMACY MARKET BY REGION,2020-2027 ($ MILLION)
  • 16. GLOBAL ONLINE PHARMACY MARKET BY REGION,2020-2027 ($ MILLION)
  • 17. GLOBAL RETAIL PHARMACY MARKET BY REGION,2020-2027 ($ MILLION)
  • 18. GLOBAL CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE,2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)
  • 23. EUROPEAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($ MILLION)
  • 24. EUROPEAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 25. EUROPEAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE,2020-2027 ($ MILLION)
  • 26. EUROPEAN CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE,2020-2027 ($ MILLION)
  • 29. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE,2020-2027 ($ MILLION)
  • 30. ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)
  • 31. REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE,2020-2027 ($ MILLION)
  • 33. REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL,2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL CARDIOVASCULAR DRUGS MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL CARDIOVASCULAR DRUGS MARKET, 2021-2027 (%)
  • 4. GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY DISEASE TYPE, 2020 VS 2027 (%)
  • 6. GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 7. GLOBAL CARDIOVASCULAR DRUGS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL ANTI-CLOTTING AGENTS MARKET BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL ANTIHYPERLIPIDEMIC MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL RENIN-ANGIOTENSIN SYSTEM BLOCKERS MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL ARRHYTHMIA MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL CORONARY ARTERY DISEASE MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL HYPERLIPIDEMIA MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL HYPERTENSION MARKET BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL PERIPHERAL ARTERY DISEASE MARKET BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL HOSPITAL PHARMACY MARKET BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL ONLINE PHARMACY MARKET BY REGION, 2020 VS 2027 (%)
  • 20. GLOBAL RETAIL PHARMACY MARKET BY REGION, 2020 VS 2027 (%)
  • 21. US CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 22. CANADA CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. UK CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. FRANCE CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. GERMANY CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. ITALY CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. SPAIN CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. REST OF EUROPE CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. INDIA CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. CHINA CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. JAPAN CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. SOUTH KOREA CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. REST OF ASIA-PACIFIC CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027($ MILLION)
  • 34. REST OF THE WORLD CARDIOVASCULAR DRUGS MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2018339

Global Cardiovascular Drug Market Research By Drug Type (Anti-Clotting Agents, Antihyperlipidemic, Calcium Channel Blockers, Renin-Angiotensin System Blockers and Other), By Disease Type (Arrhythmia, Coronary Artery Disease, Hyperlipidemia, Hypertension and Peripheral Artery Disease), and By Distribution Channel (Hospital Pharmacy, Online Pharmacy and Retail Pharmacy) Forecast Period 2021-2027

The global cardiovascular drug market is growing at a considerable CAGR of 1.2% during the forecast period. Changing life style and eating habits is one of the prime factors affecting and driving the market. Increasing pollution in the environment, rising health care expenditure among others is also estimated to be the key factors that are contributing significantly towards the growth of the market. However, high cost involvement in treatment along with strict governmental rules and regulation for approval of drug are some major factors constraints that are hindering the growth of the global cardiovascular drug market across the globe.

Further, rising spending in R&D for drug discovery by pharmaceutical companies along with diagnosis procedure adoption of genetic engineering are some of the key factors that are creating opportunities for the market. New product launches and collaboration in the market are likely to drive the growth of the global cardiovascular drug market. For instance, in July 2020, Lilly and Boehringer Ingelheim International GmbH had set forth the results related with phase 3 trial of Jardiance (empagliflozin) that had supported in reducing risks of cardiovascular diseases or hospitalization for heart failure in adults with and without diseases.

Impact of COVID-19 on the Global Cardiovascular Drug Market

The global cardiovascular drug market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted the manufacturing and transportation activities. Moreover, the proper treatment was been given by physicians to patients suffering from cardiovascular diseases.

Segmental Outlook

The market is segmented based on drug type, disease type and distribution channel. Based on drug type, the market is segmented into anti-clotting agents, antihyperlipidemic, calcium channel blockers, renin-angiotensin system blockers and other. By disease type, the market is segmented into arrhythmia, coronary artery disease, hyperlipidemia, hypertension and peripheral artery disease. Further, by distribution channel, market is segmented hospital pharmacy, online pharmacy and retail pharmacy.

Global Cardiovascular Drug Market Share by Drug Type 2020 (%)

Global Cardiovascular Drug Market Share by Drug Type

Based on the drug type, the anti-clotting agents segment holds a significant share in the market. It is one of the important drugs in order to manage cardiovascular diseases. These are drugs that are considered to be given to the patient for preventing the blood clots. When the patients are at high risk of getting clots this drug supports in reducing the chances of developing something serious in them.

Regional Outlooks

The global cardiovascular drug market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global cardiovascular drug market. Some factors that are boosting the market growth in North America are increasing pervasiveness of cardiovascular diseases along with presence of the leading players in the market. Additionally, investment in health care facility in the region and adoption of genetic engineering in the US is boosting the market in this region.

Global Cardiovascular Drug Market, by Region 2021-2027

Global Cardiovascular Drug Market, by Region

Asia-Pacific will have Considerable Growth in the Global Cardiovascular Drug Market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing alcohol consumption along with rising changes in lifestyle in emerging economies of the region are likely to drive the growth of the regional market. Further due to rising government funding in order to improve health care infrastructure in India, China and South Korea are also some of the factors that are affecting and impacting the growth in this market.

Market Player Outlook

Key players of the global cardiovascular drug market are Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Novartis Ag, and Merck & Co., Inc. among others. To survive in the market, these players adopt different marketing strategies such as product launches, merger and acquisition. For instance, in May 2020, Bristol-Myers Squibb Co. had announced the entering of merger agreement in which the company will acquire one of the clinical-stage bio-pharmaceutical company named as MyoKardia. Through this acquisition, the company had got the benefit of gaining mavacamten that is considered to be a cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy.

In December 2020, Novartis AG had received the approval from European Commission (EC) for its Leqvio (inclisiran) atherosclerotic cardiovascular disease. The Leqvio is the small entering RND that provide effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction for patients with atherosclerotic cardiovascular disease (ACD).

In March 2019, Bristol-Myers Squibb Co. had entered into merger agreement under which it will acquire Celgene corp. for approximately $74 billion. Through this transaction the acquired company will lead to be one the specialty bio-pharma company that will be addressing patients suffering from, inflammatory and immunologic disease and cardiovascular disease through scientific capabilities along with high-value innovative medicines.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global cardiovascular drug market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Cardiovascular Drug Industry
  • Recovery Scenario of Global Cardiovascular Drug Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Cardiovascular Drugs Market by Drug Type
    • 5.1.1. Anti-Clotting Agents
    • 5.1.2. Antihyperlipidemic
    • 5.1.3. Calcium Channel Blockers
    • 5.1.4. Renin-Angiotensin System Blockers
    • 5.1.5. Other
  • 5.2. Global Cardiovascular Drugs Market by Disease Type
    • 5.2.1. Arrhythmia
    • 5.2.2. Coronary Artery Disease
    • 5.2.3. Hyperlipidemia
    • 5.2.4. Hypertension
    • 5.2.5. Peripheral Artery Disease
  • 5.3. Global Cardiovascular Drugs Market by Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Online Pharmacy
    • 5.3.3. Retail Pharmacy

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott
  • 7.2. AMGEN
  • 7.3. Bayer AG
  • 7.4. Boehringer Ingelheim International GmbH
  • 7.5. Bristol-Myers Squibb Co.
  • 7.6. Catalent, Inc
  • 7.7. DAIICHI SANKYO CO., LTD.
  • 7.8. Lilly
  • 7.9. F. HOFFMANN-LA ROCHE LTD.
  • 7.10. Gilead Sciences, Inc.
  • 7.11. GlaxoSmithKline plc.
  • 7.12. Johnson & Johnson Services, Inc.
  • 7.13. Probo Medical, LLC
  • 7.14. Novartis AG
  • 7.15. Merck & Co., Inc.
  • 7.16. Otsuka Holdings Co., Ltd.
  • 7.17. Pfizer Inc.